ZA200108571B - HCV combination therapy, containing ribavirin in association with antioxidants. - Google Patents

HCV combination therapy, containing ribavirin in association with antioxidants. Download PDF

Info

Publication number: ZA200108571B
Authority: ZA; South Africa
Prior art keywords: interferon; ribavirin; alfa; treatment; weeks
Prior art date: 1999-04-19

Application number

ZA200108571A

Other languages

English (en)

Inventor

Clifford A Brass

Edward Piken

Paul W Glue

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-19

Filing date

2001-10-18

Publication date

2003-01-20

2001-10-18 Application filed by Schering Corp filed Critical Schering Corp

2003-01-20 Publication of ZA200108571B publication Critical patent/ZA200108571B/en

Links

IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims description 103
229960000329 ribavirin Drugs 0.000 title claims description 96
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims description 96
239000003963 antioxidant agent Substances 0.000 title claims description 43
238000002648 combination therapy Methods 0.000 title claims description 36
238000011282 treatment Methods 0.000 claims description 78
108010047761 Interferon-alpha Proteins 0.000 claims description 75
102000006992 Interferon-alpha Human genes 0.000 claims description 75
229950000038 interferon alfa Drugs 0.000 claims description 58
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 56
235000006708 antioxidants Nutrition 0.000 claims description 42
102000014150 Interferons Human genes 0.000 claims description 34
108010050904 Interferons Proteins 0.000 claims description 34
229940079322 interferon Drugs 0.000 claims description 32
230000003078 antioxidant effect Effects 0.000 claims description 31
108010078049 Interferon alpha-2 Proteins 0.000 claims description 30
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 25
229930003427 Vitamin E Natural products 0.000 claims description 24
229960003507 interferon alfa-2b Drugs 0.000 claims description 24
238000000034 method Methods 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 24
108010092851 peginterferon alfa-2b Proteins 0.000 claims description 24
229940046009 vitamin E Drugs 0.000 claims description 24
235000019165 vitamin E Nutrition 0.000 claims description 24
239000011709 vitamin E Substances 0.000 claims description 24
206010018910 Haemolysis Diseases 0.000 claims description 22
230000008588 hemolysis Effects 0.000 claims description 22
208000036142 Viral infection Diseases 0.000 claims description 21
230000009385 viral infection Effects 0.000 claims description 21
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims description 20
229920001223 polyethylene glycol Polymers 0.000 claims description 18
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 13
208000015181 infectious disease Diseases 0.000 claims description 12
239000002202 Polyethylene glycol Substances 0.000 claims description 10
-1 succinate ester Chemical class 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
108010092853 peginterferon alfa-2a Proteins 0.000 claims description 9
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 7
229960003521 interferon alfa-2a Drugs 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
229930003268 Vitamin C Natural products 0.000 claims description 6
230000001684 chronic effect Effects 0.000 claims description 6
230000006698 induction Effects 0.000 claims description 6
235000019154 vitamin C Nutrition 0.000 claims description 6
239000011718 vitamin C Substances 0.000 claims description 6
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
235000010841 Silybum marianum Nutrition 0.000 claims description 5
235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
235000012661 lycopene Nutrition 0.000 claims description 5
239000001751 lycopene Substances 0.000 claims description 5
OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
229960004999 lycopene Drugs 0.000 claims description 5
229910052711 selenium Inorganic materials 0.000 claims description 5
239000011669 selenium Substances 0.000 claims description 5
ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
244000272459 Silybum marianum Species 0.000 claims description 4
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
229960004308 acetylcysteine Drugs 0.000 claims description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
229940088594 vitamin Drugs 0.000 claims description 4
229930003231 vitamin Natural products 0.000 claims description 4
235000013343 vitamin Nutrition 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
235000019155 vitamin A Nutrition 0.000 claims description 4
239000011719 vitamin A Substances 0.000 claims description 4
229940045997 vitamin a Drugs 0.000 claims description 4
150000003722 vitamin derivatives Chemical class 0.000 claims description 4
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 3
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 2
235000017471 coenzyme Q10 Nutrition 0.000 claims 2
229940110767 coenzyme Q10 Drugs 0.000 claims 2
GFTUVGXUYWIPMI-BHMOCAHYSA-N (2r,3s,4r,5r,6r)-2-(hydroxymethyl)-6-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methyl]oxane-3,4,5-triol Chemical group C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GFTUVGXUYWIPMI-BHMOCAHYSA-N 0.000 claims 1
238000009093 first-line therapy Methods 0.000 claims 1
208000005176 Hepatitis C Diseases 0.000 description 24
208000010710 hepatitis C virus infection Diseases 0.000 description 17
210000002966 serum Anatomy 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
102000001554 Hemoglobins Human genes 0.000 description 13
108010054147 Hemoglobins Proteins 0.000 description 13
208000006154 Chronic hepatitis C Diseases 0.000 description 10
230000002459 sustained effect Effects 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
230000004044 response Effects 0.000 description 8
150000003712 vitamin E derivatives Chemical class 0.000 description 8
235000004835 α-tocopherol Nutrition 0.000 description 8
239000002076 α-tocopherol Substances 0.000 description 8
208000020403 chronic hepatitis C virus infection Diseases 0.000 description 7
238000010839 reverse transcription Methods 0.000 description 7
229960000984 tocofersolan Drugs 0.000 description 7
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 7
238000011529 RT qPCR Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
102100040018 Interferon alpha-2 Human genes 0.000 description 5
108010079944 Interferon-alpha2b Proteins 0.000 description 5
150000002334 glycols Chemical class 0.000 description 5
229940065638 intron a Drugs 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 4
102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
108010012770 Rebetron Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
241000700605 Viruses Species 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
238000010606 normalization Methods 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000009265 virologic response Effects 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
239000004255 Butylated hydroxyanisole Substances 0.000 description 3
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
229940043253 butylated hydroxyanisole Drugs 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000012317 liver biopsy Methods 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229940113116 polyethylene glycol 1000 Drugs 0.000 description 3
230000009467 reduction Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
229930003799 tocopherol Natural products 0.000 description 3
239000011732 tocopherol Substances 0.000 description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
102100023915 Insulin Human genes 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical group O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
241000710886 West Nile virus Species 0.000 description 2
ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
229930003836 cresol Natural products 0.000 description 2
238000011161 development Methods 0.000 description 2
229940061607 dibasic sodium phosphate Drugs 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229940045641 monobasic sodium phosphate Drugs 0.000 description 2
229910000403 monosodium phosphate Inorganic materials 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
229920000233 poly(alkylene oxides) Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000005057 refrigeration Methods 0.000 description 2
SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
229960004245 silymarin Drugs 0.000 description 2
235000017700 silymarin Nutrition 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000008227 sterile water for injection Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
235000010384 tocopherol Nutrition 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
229940100050 virazole Drugs 0.000 description 2
GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 1
GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
VVLAIYIMMFWRFW-UHFFFAOYSA-N 2-hydroxyethylazanium;acetate Chemical compound CC(O)=O.NCCO VVLAIYIMMFWRFW-UHFFFAOYSA-N 0.000 description 1
241000712891 Arenavirus Species 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
201000006306 Cor pulmonale Diseases 0.000 description 1
235000002414 D-alpha-tocopherylacetate Nutrition 0.000 description 1
239000011740 D-alpha-tocopherylacetate Substances 0.000 description 1
CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 description 1
GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000006142 Infectious Encephalitis Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
208000016028 Korean hemorrhagic fever Diseases 0.000 description 1
239000002211 L-ascorbic acid Substances 0.000 description 1
235000000069 L-ascorbic acid Nutrition 0.000 description 1
206010023927 Lassa fever Diseases 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000713112 Orthobunyavirus Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
241000320380 Silybum Species 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
108020005719 Species specific proteins Proteins 0.000 description 1
102000007397 Species specific proteins Human genes 0.000 description 1
206010041896 St. Louis Encephalitis Diseases 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
YDQXYRCYDMRJGD-UHFFFAOYSA-N chloroform;phenol;thiocyanic acid Chemical compound SC#N.ClC(Cl)Cl.OC1=CC=CC=C1 YDQXYRCYDMRJGD-UHFFFAOYSA-N 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229940039770 d-alpha-tocopheryl acetate Drugs 0.000 description 1
230000001934 delay Effects 0.000 description 1
235000010389 delta-tocopherol Nutrition 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000010382 gamma-tocopherol Nutrition 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
108010055511 interferon alfa-2c Proteins 0.000 description 1
108010006088 interferon alfa-n1 Proteins 0.000 description 1
229940109242 interferon alfa-n3 Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000007477 logistic regression Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000000820 nonprescription drug Substances 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
229930003802 tocotrienol Natural products 0.000 description 1
239000011731 tocotrienol Substances 0.000 description 1
229940068778 tocotrienols Drugs 0.000 description 1
235000019148 tocotrienols Nutrition 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
125000001020 α-tocopherol group Chemical group 0.000 description 1
235000007680 β-tocopherol Nutrition 0.000 description 1
239000011590 β-tocopherol Substances 0.000 description 1
239000002478 γ-tocopherol Substances 0.000 description 1
QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
239000002446 δ-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

ZA200108571A 1999-04-19 2001-10-18 HCV combination therapy, containing ribavirin in association with antioxidants. ZA200108571B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29468799A	1999-04-19	1999-04-19

Publications (1)

Publication Number	Publication Date
ZA200108571B true ZA200108571B (en)	2003-01-20

Family

ID=23134504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200108571A ZA200108571B (en)	1999-04-19	2001-10-18	HCV combination therapy, containing ribavirin in association with antioxidants.

Country Status (14)

Country	Link
EP (1)	EP1046399A1 (fr)
JP (1)	JP2002542202A (fr)
CN (1)	CN1355708A (fr)
AR (1)	AR023541A1 (fr)
AU (1)	AU4463300A (fr)
BR (1)	BR0009840A (fr)
CA (1)	CA2306039A1 (fr)
CO (1)	CO5241354A1 (fr)
HU (1)	HUP0200942A3 (fr)
MX (1)	MXPA00003974A (fr)
NO (1)	NO20015059L (fr)
PE (1)	PE20010284A1 (fr)
WO (1)	WO2000062799A1 (fr)
ZA (1)	ZA200108571B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
AU2001235278A1 (en)	2000-02-18	2001-08-27	Shire Biochem Inc	Method for the treatment or prevention of flavivirus infections using nucleoside analogues
EP1450836A4 (fr) *	2000-11-03	2007-07-25	Intarcia Therapeutics Inc	Procede pour une dosimetrie de medicaments a court et a long terme
ITMI20011863A1 (it) *	2001-09-05	2003-03-05	Zambon Spa	Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (fr) *	2001-09-20	2003-03-27	Schering Corporation	Polytherapie de l'hepatite c
US20040022873A1 (en) *	2001-11-09	2004-02-05	Guilford F. Timothy	Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
ATE353658T1 (de) *	2002-06-03	2007-03-15	Nat Health Research Institutes	Behandlung von flavivirusinfizierungen
AU2003294757A1 (en) *	2002-11-29	2004-06-23	Axxima Pharmaceuticals Ag	Formulations useful against hepatitis c virus infections
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004073706A1 (fr) *	2003-02-21	2004-09-02	Mochida Pharmaceutical Co., Ltd.	Medicament destine a attenuer les effets secondaires dans la therapie combinee interferon ribaverine
CA2535451A1 (fr) *	2003-08-13	2005-02-24	Howard J. Smith & Associates Pty Ltd.	Methode de traitement d'infections virales
WO2005120479A1 (fr) *	2004-06-09	2005-12-22	Gpc Biotech Ag	Utilisation de selenium ou d'un sel de selenium et d'un acide retinoique ou d'un retinoide pour traiter une hepatite c virale
WO2006083761A2 (fr)	2005-02-03	2006-08-10	Alza Corporation	Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
AU2007266475B2 (en)	2006-05-30	2009-12-03	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
NZ574524A (en)	2006-08-09	2011-07-29	Intarcia Therapeutics Inc	Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
AU2008244523B2 (en)	2007-04-23	2012-02-16	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
CA2726861C (fr)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
WO2011037623A1 (fr)	2009-09-28	2011-03-31	Intarcia Therapeutics, Inc.	Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
CN107898791A (zh)	2010-06-03	2018-04-13	药品循环有限责任公司	布鲁顿酪氨酸激酶(btk)抑制剂的应用
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) *	2011-11-23	2013-05-23	Thomas Christian Lines	Method for treating hepatitis c virus infection using quercetin-containing compositions
KR20150032340A (ko)	2012-07-24	2015-03-25	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
BR112015010059A2 (pt)	2012-11-02	2017-07-11	Pharmacyclics Inc	terapia adjuvante com inibidor da quinase da família tec
US9885086B2 (en)	2014-03-20	2018-02-06	Pharmacyclics Llc	Phospholipase C gamma 2 and resistance associated mutations
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (fr)	2015-06-03	2023-10-04	i2o Therapeutics, Inc.	Systèmes de mise en place d'implant
AU2017268161B2 (en)	2016-05-16	2020-03-12	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CA3049034A1 (fr)	2017-01-03	2018-07-12	Intarcia Therapeutics, Inc.	Methodes comprenant l'administration continue d'un agoniste du recepteur glp-1 et la co-adminstration d'un medicament

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5157998A (en) *	1996-11-01	1998-05-29	Thomas Najarian	Methods and compositions for treatment of hepatitis c infection

2000
- 2000-04-18 CO CO00028688A patent/CO5241354A1/es not_active Application Discontinuation
- 2000-04-18 EP EP20000303246 patent/EP1046399A1/fr not_active Withdrawn
- 2000-04-18 AU AU44633/00A patent/AU4463300A/en not_active Abandoned
- 2000-04-18 JP JP2000611935A patent/JP2002542202A/ja active Pending
- 2000-04-18 CN CN00808831A patent/CN1355708A/zh active Pending
- 2000-04-18 HU HU0200942A patent/HUP0200942A3/hu unknown
- 2000-04-18 AR ARP000101815A patent/AR023541A1/es unknown
- 2000-04-18 CA CA002306039A patent/CA2306039A1/fr not_active Abandoned
- 2000-04-18 WO PCT/US2000/010240 patent/WO2000062799A1/fr active Application Filing
- 2000-04-18 BR BR0009840-0A patent/BR0009840A/pt not_active IP Right Cessation
- 2000-04-19 MX MXPA00003974A patent/MXPA00003974A/es unknown
- 2000-04-19 PE PE2000000373A patent/PE20010284A1/es not_active Application Discontinuation
2001
- 2001-10-18 NO NO20015059A patent/NO20015059L/no not_active Application Discontinuation
- 2001-10-18 ZA ZA200108571A patent/ZA200108571B/en unknown

Also Published As

Publication number	Publication date
HUP0200942A2 (hu)	2002-07-29
AR023541A1 (es)	2002-09-04
JP2002542202A (ja)	2002-12-10
BR0009840A (pt)	2002-01-08
MXPA00003974A (es)	2002-03-08
PE20010284A1 (es)	2001-03-05
EP1046399A1 (fr)	2000-10-25
NO20015059L (no)	2001-12-19
HUP0200942A3 (en)	2003-03-28
NO20015059D0 (no)	2001-10-18
CN1355708A (zh)	2002-06-26
CO5241354A1 (es)	2003-01-31
WO2000062799A1 (fr)	2000-10-26
CA2306039A1 (fr)	2000-10-19
AU4463300A (en)	2000-11-02

Publication	Publication Date	Title
ZA200108571B (en)	2003-01-20	HCV combination therapy, containing ribavirin in association with antioxidants.
US20030055013A1 (en)	2003-03-20	HCV combination therapy
US6849254B1 (en)	2005-02-01	HCV combination therapy
EP0956861B1 (fr)	2002-04-24	Thérapie combinatoire conténant de la ribavirine et de l'interferon alpha chez les patients ayant une infection chronique d'hépatite C et n'ayant pas été traités par un agent antiviral
EP0903148B1 (fr)	2001-10-10	Thérapie combinée pour l'éradication de hcv-arn détectable chez des patients ayant une infection d'hépatite C chronique
US20020127203A1 (en)	2002-09-12	Ribavirin-pegylated interferon alfa HCV combination therapy
US6472373B1 (en)	2002-10-29	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en)	2001-01-09	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1140143A2 (fr)	2001-10-10	Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine
US6824768B2 (en)	2004-11-30	Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037097A1 (fr)	2000-06-29	Polytherapie contre le virus de l'hepatite c, au moyen de la ribavirine et de l'induction de l'interferon alpha